Telavancin (vibativ), a new option for the treatment of gram-positive infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

1. Cyclic peptide drugs approved in the last two decades (2001-2021).RSC chemical biology · 2022
   Review
2. Alternatives to Fight Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021
   Review
3. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Antimicrobial agents and chemotherapy · 2017
   Article
4. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.Therapeutic advances in infectious disease · 2017
   Review
5. Update on the emerging role of telavancin in hospital-acquired infections.Therapeutics and clinical risk management · 2015
   Review
6. Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS.Journal of pharmaceutical and biomedical analysis · 2014
   Article
7. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Expert review of clinical pharmacology · 2014
   Review
8. In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.Ochsner journal · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.